These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 38882528)

  • 1. Bispecific CAR-T cells targeting FAP and GPC3 have the potential to treat hepatocellular carcinoma.
    Zhou L; Li Y; Zheng D; Zheng Y; Cui Y; Qin L; Tang Z; Peng D; Wu Q; Long Y; Yao Y; Wong N; Lau J; Li P
    Mol Ther Oncol; 2024 Jun; 32(2):200817. PubMed ID: 38882528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma.
    Wang H; Wang X; Ye X; Ju Y; Cao N; Wang S; Cai J
    BMC Cancer; 2022 Jul; 22(1):814. PubMed ID: 35879685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GPC3-targeted CAR-T cells secreting B7H3-targeted BiTE exhibit potent cytotoxicity activity against hepatocellular carcinoma cell in the in vitro assay.
    Cao G; Zhang G; Liu M; Liu J; Wang Q; Zhu L; Wan X
    Biochem Biophys Rep; 2022 Sep; 31():101324. PubMed ID: 36032401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Shed antigen-induced blocking effect on CAR-T cells targeting Glypican-3 in Hepatocellular Carcinoma.
    Sun L; Gao F; Gao Z; Ao L; Li N; Ma S; Jia M; Li N; Lu P; Sun B; Ho M; Jia S; Ding T; Gao W
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33833049
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GPC3-IL7-CCL19-CAR-T primes immune microenvironment reconstitution for hepatocellular carcinoma therapy.
    Lu LL; Xiao SX; Lin ZY; Bai JJ; Li W; Song ZQ; Zhou YH; Lu B; Wu WZ
    Cell Biol Toxicol; 2023 Dec; 39(6):3101-3119. PubMed ID: 37853185
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of T cells carrying two complementary chimeric antigen receptors against glypican-3 and asialoglycoprotein receptor 1 for the treatment of hepatocellular carcinoma.
    Chen C; Li K; Jiang H; Song F; Gao H; Pan X; Shi B; Bi Y; Wang H; Wang H; Li Z
    Cancer Immunol Immunother; 2017 Apr; 66(4):475-489. PubMed ID: 28035433
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term complete response of advanced hepatocellular carcinoma to glypican-3 specific chimeric antigen receptor T-Cells plus sorafenib, a case report.
    Sun H; Xing C; Jiang S; Yu K; Dai S; Kong H; Jin Y; Shan Y; Yang W; Wang Z; Xiao J; Wang H; Wang W; Li Z; Shi K
    Front Immunol; 2022; 13():963031. PubMed ID: 36059488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GPC3-targeted CAR-T cells expressing GLUT1 or AGK exhibit enhanced antitumor activity against hepatocellular carcinoma.
    Sun RX; Liu YF; Sun YS; Zhou M; Wang Y; Shi BZ; Jiang H; Li ZH
    Acta Pharmacol Sin; 2024 Sep; 45(9):1937-1950. PubMed ID: 38750075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Armored Inducible Expression of IL-12 Enhances Antitumor Activity of Glypican-3-Targeted Chimeric Antigen Receptor-Engineered T Cells in Hepatocellular Carcinoma.
    Liu Y; Di S; Shi B; Zhang H; Wang Y; Wu X; Luo H; Wang H; Li Z; Jiang H
    J Immunol; 2019 Jul; 203(1):198-207. PubMed ID: 31142602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GPC3-targeted CAR-M cells exhibit potent antitumor activity against hepatocellular carcinoma.
    Guan L; Wu S; Zhu Q; He X; Li X; Song G; Zhang L; Yin X
    Biochem Biophys Rep; 2024 Sep; 39():101741. PubMed ID: 38881757
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Construction and function of Glypican-3-targeted fourth-generation chimeric antigen receptor T cells (secreting IL-7 and CCL19)].
    Huang W; Liu Y; Hu Y; Gao J
    Sheng Wu Gong Cheng Xue Bao; 2020 May; 36(5):979-991. PubMed ID: 32567281
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glypican-3-Specific CAR T Cells Coexpressing IL15 and IL21 Have Superior Expansion and Antitumor Activity against Hepatocellular Carcinoma.
    Batra SA; Rathi P; Guo L; Courtney AN; Fleurence J; Balzeau J; Shaik RS; Nguyen TP; Wu MF; Bulsara S; Mamonkin M; Metelitsa LS; Heczey A
    Cancer Immunol Res; 2020 Mar; 8(3):309-320. PubMed ID: 31953246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of GPC3 and EGFR-dual-targeting chimeric antigen receptor-T cells for adoptive T cell therapy.
    Li K; Qian S; Huang M; Chen M; Peng L; Liu J; Xu W; Xu J
    Am J Transl Res; 2021; 13(1):156-167. PubMed ID: 33527015
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Persistent Polyfunctional Chimeric Antigen Receptor T Cells That Target Glypican 3 Eliminate Orthotopic Hepatocellular Carcinomas in Mice.
    Li D; Li N; Zhang YF; Fu H; Feng M; Schneider D; Su L; Wu X; Zhou J; Mackay S; Kramer J; Duan Z; Yang H; Kolluri A; Hummer AM; Torres MB; Zhu H; Hall MD; Luo X; Chen J; Wang Q; Abate-Daga D; Dropulic B; Hewitt SM; Orentas RJ; Greten TF; Ho M
    Gastroenterology; 2020 Jun; 158(8):2250-2265.e20. PubMed ID: 32060001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma.
    Gao H; Li K; Tu H; Pan X; Jiang H; Shi B; Kong J; Wang H; Yang S; Gu J; Li Z
    Clin Cancer Res; 2014 Dec; 20(24):6418-28. PubMed ID: 25320357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular Carcinoma.
    Guo X; Jiang H; Shi B; Zhou M; Zhang H; Shi Z; Du G; Luo H; Wu X; Wang Y; Sun R; Li Z
    Front Pharmacol; 2018; 9():1118. PubMed ID: 30327605
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma.
    Chen S; Gong F; Liu S; Xie Y; Ye X; Lin X; Wang X; Zheng Q; Liu Q; Sun Y
    Clin Exp Med; 2024 Aug; 24(1):204. PubMed ID: 39196390
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC.
    Du K; Li Y; Liu J; Chen W; Wei Z; Luo Y; Liu H; Qi Y; Wang F; Sui J
    Mol Ther; 2021 Apr; 29(4):1572-1584. PubMed ID: 33429083
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BOXR1030, an anti-GPC3 CAR with exogenous GOT2 expression, shows enhanced T cell metabolism and improved anti-cell line derived tumor xenograft activity.
    Hickman TL; Choi E; Whiteman KR; Muralidharan S; Pai T; Johnson T; Parikh A; Friedman T; Gilbert M; Shen B; Barron L; McGinness KE; Ettenberg SA; Motz GT; Weiss GJ; Jensen-Smith A
    PLoS One; 2022; 17(5):e0266980. PubMed ID: 35507536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.